Turnstone is focused on developing new medicines to treat and cure solid tumors. Despite advancements in immunotherapy, many patients face poor outcomes or relapse. Turnstone addresses this challenge by pioneering next-generation tumor-infiltrating lymphocyte (TIL) therapies, selecting potent and tumor-reactive T cells. These therapies aim to improve responses in patients with solid tumors, potentially offering curative treatments across multiple cancer types.